BACKGROUND: The "clinical high risk" (CHR) construct was developed to identify individuals at imminent risk of developing psychosis. However, most individuals identified as CHR do not convert to psychosis, and it is unknown whether these nonconverting individuals actually recover from an at-risk state. METHODS: Eighty-four prospectively identified patients meeting CHR criteria, and 58 healthy comparison subjects were followed in a 2-year longitudinal study. Analyses examined rates of conversion, clinical, and functional recovery. Proportional cause-specific hazard models were used to examine the effects of baseline and time-varying predictors on conversion and remission. Trajectories of symptoms and psychosocial functioning measures were compared across outcome groups. RESULTS: Competing risk survival analyses estimated that 30% of CHR subjects convert to psychosis by 2 years, while 36% symptomatically remit and 30% functionally recover by 2 years. Lower levels of negative and mood/anxiety symptoms were related to increased likelihood of both symptomatic and functional recovery. CHR subjects who remitted symptomatically were more similar to healthy controls in terms of both their baseline and longitudinal symptoms and functioning than the other outcome groups. CONCLUSIONS: Nonconverting CHR cases represented a heterogeneous group. Given that nonconverted subjects who remitted symptomatically also presented initially with less severe prodromal symptomatology and showed a distinct normative trajectory of both symptoms and psychosocial functioning over time, it may be possible to refine the CHR criteria to reduce the number of "false positive" cases by eliminating those who present with less severe attenuated positive symptoms or show early improvements in terms of symptoms or functioning.
BACKGROUND: The "clinical high risk" (CHR) construct was developed to identify individuals at imminent risk of developing psychosis. However, most individuals identified as CHR do not convert to psychosis, and it is unknown whether these nonconverting individuals actually recover from an at-risk state. METHODS: Eighty-four prospectively identified patients meeting CHR criteria, and 58 healthy comparison subjects were followed in a 2-year longitudinal study. Analyses examined rates of conversion, clinical, and functional recovery. Proportional cause-specific hazard models were used to examine the effects of baseline and time-varying predictors on conversion and remission. Trajectories of symptoms and psychosocial functioning measures were compared across outcome groups. RESULTS: Competing risk survival analyses estimated that 30% of CHR subjects convert to psychosis by 2 years, while 36% symptomatically remit and 30% functionally recover by 2 years. Lower levels of negative and mood/anxiety symptoms were related to increased likelihood of both symptomatic and functional recovery. CHR subjects who remitted symptomatically were more similar to healthy controls in terms of both their baseline and longitudinal symptoms and functioning than the other outcome groups. CONCLUSIONS: Nonconverting CHR cases represented a heterogeneous group. Given that nonconverted subjects who remitted symptomatically also presented initially with less severe prodromal symptomatology and showed a distinct normative trajectory of both symptoms and psychosocial functioning over time, it may be possible to refine the CHR criteria to reduce the number of "false positive" cases by eliminating those who present with less severe attenuated positive symptoms or show early improvements in terms of symptoms or functioning.
Authors: Stephanie E Meyer; Carrie E Bearden; Sabrina R Lux; Jamie L Gordon; Jennifer K Johnson; Mary P O'Brien; Tara A Niendam; Rachel L Loewy; Joseph Ventura; Tyrone D Cannon Journal: J Child Adolesc Psychopharmacol Date: 2005-06 Impact factor: 2.576
Authors: Tandy J Miller; Thomas H McGlashan; Joanna Lifshey Rosen; Lubna Somjee; Philip J Markovich; Kelly Stein; Scott W Woods Journal: Am J Psychiatry Date: 2002-05 Impact factor: 18.112
Authors: Barbara A Cornblatt; Andrea M Auther; Tara Niendam; Christopher W Smith; Jamie Zinberg; Carrie E Bearden; Tyrone D Cannon Journal: Schizophr Bull Date: 2007-04-17 Impact factor: 9.306
Authors: Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona M Francey; Colleen A McFarlane; Mats Hallgren; Patrick D McGorry Journal: Schizophr Res Date: 2003-03-01 Impact factor: 4.939
Authors: Vijay A Mittal; Derek J Dean; Jessica A Bernard; Joseph M Orr; Andrea Pelletier-Baldelli; Emily E Carol; Tina Gupta; Jessica Turner; Daniel R Leopold; Briana L Robustelli; Zachary B Millman Journal: Schizophr Bull Date: 2013-12-27 Impact factor: 9.306
Authors: Danielle McLaughlin; Ricardo E Carrión; Andrea M Auther; Doreen M Olvet; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Robert K Heinssen; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Terry E Goldberg; Philip D Harvey; Barbara A Cornblatt Journal: Schizophr Bull Date: 2016-04-22 Impact factor: 9.306
Authors: A Masillo; L R Valmaggia; R Saba; M Brandizzi; J F Lindau; A Solfanelli; M Curto; F Narilli; L Telesforo; G D Kotzalidis; D Di Pietro; M D'Alema; P Girardi; P Fiori Nastro Journal: Eur Child Adolesc Psychiatry Date: 2015-02-25 Impact factor: 4.785
Authors: Daniel Fulford; Tara A Niendam; Erin G Floyd; Cameron S Carter; Daniel H Mathalon; Sophia Vinogradov; Barbara K Stuart; Rachel L Loewy Journal: Schizophr Res Date: 2013-04-12 Impact factor: 4.939
Authors: Ricardo E Carrión; Andrea M Auther; Danielle McLaughlin; Ruth Olsen; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Barbara A Cornblatt Journal: Schizophr Bull Date: 2019-06-18 Impact factor: 9.306
Authors: Joseph S DeLuca; Nicole D Andorko; Doha Chibani; Samantha Y Jay; Pamela J Rakhshan Rouhakhtar; Emily Petti; Mallory J Klaunig; Elizabeth C Thompson; Zachary B Millman; Kathleen M Connors; LeeAnn Akouri-Shan; John Fitzgerald; Samantha L Redman; Caroline Roemer; Miranda A Bridgwater; Jordan E DeVylder; Cheryl A King; Steven C Pitts; Shauna P Reinblatt; Heidi J Wehring; Kristin L Bussell; Natalee Solomon; Sarah M Edwards; Gloria M Reeves; Robert W Buchanan; Jason Schiffman Journal: J Psychother Integr Date: 2020-06